Input Parameters | Mean | Lower bound | Upper bound | Source |
---|---|---|---|---|
Mortality rate with appropriate empiric treatment | 0.013 | 0.012 | 0.014 | Edelsberg et al. [13] |
Mortality rate with inappropriate empiric antibiotic | 0.095 | 0.086 | 0.105 | Edelsberg et al. [13] |
Duration of empiric therapy | 3 days | 3 days | 3 days | Assumption |
Total LOS for IAAT (inc. empiric therapy) | 6.9 days | 6.8 days | 7 days | Edelsberg et al. [13] |
Total LOS for IIAT (inc. empiric therapy) | 11.5 days | 11.3 days | 11.9 days | Edelsberg et al. [13] |
Health utility for survivors | 0.85 | 0.70 | 1.00 | Assumption based on Jansen et al. [25] |
Discount rate | 3.0% | 3.0% | 3.0% | AMCP [26] |
Hospital cost per day (average) | $2558.55 | $2046.84 | $3070.26 | HCUP [27] |
Drug acquisition costs per day | ||||
Ceftolozane/tazobactam plus metronidazole | $253.20 | Analy$ource [29] | ||
Aztreonam | $84.24 | Analy$ource [29] | ||
Cefepime | $23.04 | Analy$ource [29] | ||
Ceftazidime | $36.66 | Analy$ource [29] | ||
Ceftriaxone | $6.40 | Analy$ource [29] | ||
Ciprofloxacin | $5.26 | Analy$ource [29] | ||
Doripenem | $125.22 | Analy$ource [29] | ||
Imipenem | $73.12 | Analy$ource [29] | ||
Levofloxacin | $6.24 | Analy$ource [29] | ||
Meropenem | $81.51 | Analy$ource [29] | ||
Piperacillin/tazobactam | $43.08 | Analy$ource [29] | ||
Tigecycline | $238.34 | Analy$ource [29] | ||
Salvagea | $164.31 | Analy$ource [29] | ||
Health care expenditure incurred per year | ||||
<25 years | $477 | Basu [18] | ||
25 to 34 years | $790 | Basu [18] | ||
35 to 44 years | $947 | Basu [18] | ||
45 to 54 years | $1422 | Basu [18] | ||
55 to 64 years | $2106 | Basu [18] | ||
65 to 74 years | $2758 | Basu [18] | ||
75 years and above | $3100 | Basu [18] |